Crohn's Disease Treatment Market size was over USD 13.48 billion in 2023 and is expected to exceed USD 23.01 billion by the end of 2036, growing at over 4.2% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of crohn's disease treatment is evaluated at USD 13.93 billion.
Increasing incidence of bowel disorders such as Crohn's disease due to lifestyle changes, rising awareness about Crohn's disease and the availability of treatments is expected to fuel this market progress. The growth of the market can also be attributed to the rising prevalence of Crohn’s disease amongst individuals on a global level.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
4.2% |
|
Base Year Market Size (2023) |
USD 13.48 billion |
|
Forecast Year Market Size (2036) |
USD 23.01 billion |
|
Regional Scope |
|
On the basis of type, the crohn's disease treatment market is segmented into Ileocolitis, Ileitis, Granulomatous colitis, Gastroduodenal Crohn's Disease, Jejunoileitis, and Perianal Crohn’s Disease. Out of which, the Ileocolitis segment is anticipated to garner largest share as this is the most common type of Crohn's disease. It causes inflammation of the lower portion of the small intestine, or ileum, and the large intestine, or colon.
On the basis of treatment, the market is segmented into surgical and non-surgical. Out of these two, non-surgical holds the highest share, over the forecast period. Non-surgical is further divided into anti-inflammatory, immune system suppressors, antibiotics, and others. In 2020, the anti-inflammatory segment was the largest segment of the market due to its greater efficacy compared to analgesic and immunosuppressants, while the immune system suppressors segment is expected to be the fastest-growing segment due to the reduction in surgeries and hospitalization rates.
On the basis of end users, the market is segmented into hospitals and clinics, research institutes, and others. The hospitals segment is expected to hold the highest share of the market as a considerable portion of the population with Crohn’s disease on a global level tend to choose healthcare facilities specializing in its treatment.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Treatment |
|
|
By End User |
|
Geographically, the crohn's disease treatment market is segmented into North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa region. The market in the Asia Pacific industry is poised to account for largest revenue share by 2036, owing to increasing awareness about Crohn’s disease, and need to develop innovative inflammatory bowel disease treatment solutions in the region. Increasing R&D of biosimilars for the treatment of Crohn’s disease is expected to boost growth of the market in the Asia Pacific. In 2021, the market in North America is evaluated to occupy the largest share in terms of revenue, owing to the R&D of novel biosimilars and drugs for the Crohn’s disease treatment. For instance, in August 2016, the U.S. Food and Drug Administration (FDA) approved two biosimilars Amjevita and Erelzi, manufactured by Amgen to treat inflammatory bowel disease.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?